Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT04736589 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Inetetamab
DRUG: Rapamycin
DRUG: Pyrotinib
DRUG: Chemotherapy

Sponsor

Peking Union Medical College